article thumbnail

Surgical and transcatheter aortic valve interventions for aortic stenosis in England: sociodemographic variations in treatment trends and outcome over 20 years

Heart BMJ

The sociodemographic characteristics of patients undergoing intervention for aortic stenosis (AS) in England, and the impact of COVID-19, is unknown. Background Health inequalities in cardiovascular care have been identified in the UK.

article thumbnail

TAVR System Shows Durable Clinical Outcomes, Strong Valve Performance in Low-Risk Aortic Stenosis Patients

DAIC

tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Two-Year Outcomes of the Five-Year SMART Trial, presented at CRT 2025. Reardon, M.D., Additional findings at five years include: Numerically lower rate of cardiovascular mortality (7.2%

TAVR 52
article thumbnail

Altshock-2: Early IABP Implantation Does Not Improve Outcomes For HF-CS

American College of Cardiology

Implantation of an intra-aortic balloon pump (IABP) did not improve 60-day survival or bridge to heart replacement (HRT) therapies in patients with heart failure-cardiogenic shock (HF-CS) compared to standard care, according to a study presented during a Featured Clinical Research session at ACC.25

article thumbnail

Management of bicuspid aortic valve disease in the transcatheter aortic valve implantation era

Heart BMJ

In an era of rapidly expanding use of transcatheter aortic valve implantation (TAVI), the management of patients with bicuspid aortic valve (BAV) disease is far less well established than in those with trileaflet anatomy.

article thumbnail

Pulse pressure and aortic valve peak velocity and incident heart failure after myocardial infarction: a cohort study

Heart BMJ

Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. to 1.97), and a similar association was observed for aortic valve peak velocity (HR: 1.37, 95% CI 1.19 m/s had a 2.10-fold

article thumbnail

Early experience with a novel transapical transcatheter aortic valve system in patients with severe aortic stenosis: a prospective, multicenter study

Frontiers in Cardiovascular Medicine

ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc., Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4

article thumbnail

Optimal antithrombotic therapy after transcatheter aortic valve replacement: a comprehensive review

Frontiers in Cardiovascular Medicine

Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.